SUZHOU, China, Sept. 5, 2023 /PRNewswire/ -- Recently, NyokAssist™ was first-in-man (FIM) use, supporting High-risk PCI completed by Dr. Junbo Ge's team from Zhongshan Hospital in Shanghai. This ...
TCT 1805: Successful Multivessel PCI for Severe LV Dysfunction and Anomalous RCA Origin With the Aid of a Novel 9F Expandable Ventricular Assist Device Receive the the latest news, research, and ...
Phoenix, AZ, (May 18, 2023) - Findings from the first-in-human trial of a novel percutaneous ventricular assist device (pVAD) were presented today as late-breaking clinical research at the Society for ...
The data presented is from an adjunct study of PROTECT III, the ongoing, prospective FDA post-approval study for Impella in high-risk PCI. The research is authored by William O’Neill, MD, medical ...
Impella 2.5, the main product for Danvers, MA-based Abiomed Inc., has received FDA premarket approval (PMA) for use in elective and urgent high-risk percutaneous coronary intervention (PCI) procedures ...
Whether revascularization by percutaneous coronary intervention (PCI) can improve event-free survival and left ventricular function in patients with severe ischemic left ventricular systolic ...
CLEVELAND, University Hospitals Case Medical Center physicians in the Harrington Heart & Vascular Institute were the first in the state of Ohio to implant a revolutionary device to treat right ...
Patients with cardiogenic shock treated at hospitals with a higher volume of percutaneous microaxial VAD implantation in the US have lower mortality risk. Higher hospital procedure volume of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results